BALA CYNWYD, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Silence Therapeutics plc (Nasdaq – SLN)
Under the terms of the Merger Agreement, Silence Therapeutics will be acquired by Merck KGaA, Darmstadt, Germany, for $20.00 per American Depositary Share (“ADS”) in an all-cash transaction with an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion, with each ADS representing three ordinary shares of Silence (or approximately $6.67 per ordinary share). The investigation concerns whether the Silence Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/silence-therapeutics-plc-nasdaq-sln/.
Option Care Health, Inc. (Nasdaq – OPCH)
Under the terms of the Merger Agreement, Option Health Care will be acquired by CD&R and McKesson Corporation (NYSE - MCK) for $32.05 per share, a total enterprise value of approximately $5.8 billion. The investigation concerns whether the Option Care Health Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/option-care-health-inc-nasdaq-opch/.
RXO Inc. (NYSE – RXO)
Under the terms of the Merger Agreement, RXO will be acquired by C.H. Robinson Worldwide, Inc. (Nasdaq - CHRW) in a stock-and-cash transaction where RXO stockholders will receive $17.25 per share in cash and 0.0856 shares of C.H. Robinson common stock for each RXO share they own, representing an implied total consideration of $30.25 per share, and an implied value of $5.8 billion. The investigation concerns whether the RXO Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/rxo-inc-nyse-rxo/.
Sangoma Technologies Corporation (Nasdaq – SANG)
Under the terms of the Merger Agreement, Sangoma will be acquired by BRC Group Holdings, Inc. (Nasdaq - RILY) for $4.25 per share in cash and 0.04767 of a share of common stock of BRC, an implied value of $5.225 per share. The investigation concerns whether the Sangoma Technologies Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/sangoma-technologies-corporation-nasdaq-sang/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
